BRAF V600E in CLL is very rare (~1-3%); does not change standard management (BTKi or vene...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-CLL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CLL |
| Sources | SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-CLL |
| ESCAT tier | IIIB |
| Evidence summary | BRAF V600E in CLL is very rare (~1-3%); does not change standard management (BTKi or venetoclax-based fixed-duration). Tissue- agnostic BRAFi off-label only. |
Notes
ESCAT IIIB. CLL algorithm primarily driven by IGHV / TP53 / del(17p) status.
Used By
No reverse references found in the YAML corpus.